Diclofenac for Plantar Fasciitis
Diclofenac topical formulations are not recommended as a primary treatment for plantar fasciitis, as the available evidence specifically addresses osteoarthritis of the knee rather than plantar fasciitis, and current plantar fasciitis guidelines do not include NSAIDs as a recommended intervention.
Evidence Assessment
The provided evidence does not support diclofenac use for plantar fasciitis:
No guideline support: The most recent plantar fasciitis clinical practice guidelines 1 and comprehensive treatment frameworks 2 do not recommend topical or oral NSAIDs as part of the evidence-based treatment algorithm for plantar fasciitis.
Wrong indication: The FDA-approved diclofenac topical solution 3 and supporting research 4 specifically target osteoarthritis of the knee, not plantar fasciitis. The mechanism of action and tissue penetration requirements differ significantly between knee joint inflammation and plantar fascia pathology.
Mismatched pathophysiology: While older guidelines mention topical diclofenac for general pain conditions 5, 6, plantar fasciitis involves degenerative changes and microtears in the plantar fascia rather than the inflammatory arthropathy that NSAIDs effectively target.
Evidence-Based Treatment Approach for Plantar Fasciitis
Based on current evidence 2, 1, the appropriate treatment hierarchy is:
Initial Phase (First-line treatments)
- Stretching exercises: Plantar fascia-specific and Achilles tendon stretching
- Orthotics and proper footwear: Custom or prefabricated arch supports
- Activity modification: Avoid barefoot walking and high-impact activities
- Ice application: 15-20 minutes after activities
Intermediate Phase (Persistent symptoms beyond 6-8 weeks)
- Extracorporeal shock wave therapy (ESWT): Superior outcomes at 6 months compared to corticosteroid injections 7
- Photobiomodulation therapy (PBMT)
- Night splints: Maintain dorsiflexion during sleep
Specialized Phase (Refractory cases beyond 3-6 months)
- Platelet-rich plasma (PRP): Demonstrates better VAS scores at 3 and 6 months compared to corticosteroid injections 7
- Corticosteroid injections: Use cautiously due to inferior long-term outcomes and plantar fascia rupture risk 7
Surgical Phase (Last resort after 12+ months of conservative failure)
- Endoscopic plantar fascia release
Critical Caveats
Avoid corticosteroid injections as first-line therapy: Meta-analysis shows significantly worse pain scores at 3 months (MD = 0.62, P = 0.01) and 6 months (MD = 1.49, P = 0.02) compared to PRP, with worse functional outcomes (AOFAS scores) at 6 months 7.
Do not use oral NSAIDs routinely: While not explicitly contraindicated, they lack evidence for plantar fasciitis efficacy and carry cardiovascular risks (increased MI risk with diclofenac: RR 1.63 for vascular events) 8 and gastrointestinal complications 9.
If considering NSAIDs for short-term pain control: Use the lowest effective dose for the shortest duration. Naproxen has the most favorable cardiovascular profile among NSAIDs 8. Screen for cardiovascular risk factors, history of GI bleeding, renal impairment, and concurrent anticoagulant use 9.
Bottom Line
Prioritize evidence-based plantar fasciitis treatments (stretching, orthotics, ESWT, PRP) rather than diclofenac, which lacks supporting data for this specific condition. If systemic pain control is needed during the initial treatment phase, consider acetaminophen (up to 2600 mg/day) as a safer alternative with fewer systemic risks 6.